Literature DB >> 18248272

Cost-effectiveness of left ventricular-assist devices in end-stage heart failure.

Julia Hutchinson1, David A Scott, Andrew J Clegg, Emma Loveman, Pam Royle, Jackie Bryant, Jill L Colquitt.   

Abstract

With a limited supply of donor hearts, individuals with end-stage heart failure have been offered hope through the use of mechanical devices. Left ventricular-assist devices (LVADs) are a technology designed to work in parallel with the heart but have yet to see widespread use since uncertainty remains as to the cost-effectiveness of this evolving new technology. We have systematically reviewed evidence of cost-effectiveness for LVADs in the bridge-to-transplant and long-term chronic support indications. A total of 18 studies reporting costs were identified. Of these, only four studies reported results in cost-effectiveness terms; two in cost per life-year saved and two in cost per quality-adjusted life-year (QALY). The majority of the other studies were simple cost summations (cost per day or incremental cost) without consideration of efficacy. In the bridge-to-transplant indication, a Danish abstract reported a cost per life-year saved of DKK270k (US$48,000), a UK study reported a cost per QALY of GB pound39,787 (US$78,000) and a Canadian study reported a cost per life-year saved of Can$91,332 (US$86,000). Regarding the long-term chronic support indication, the same Canadian study reported a cost per life-year saved of Can$59,842 (US$56,000), whereas a US study reported a cost per QALY of $36,255-60,057. Assuming a willingness to pay the threshold of GB pound30,000 (US$59,000) per QALY, there is arguably stronger evidence to support the cost-effectiveness of LVAD technology for the long-term chronic support indication. However, the methodological quality of the majority of studies was poor, as was their generalizability, raising concerns over the reliability of these figures. With the limited and declining availability of donor hearts for transplantation, it appears that the future of this technology is in its use as long-term chronic support. Further analyses should be undertaken, particularly alongside randomized, controlled trials and utilizing second- and third-generation devices.

Entities:  

Mesh:

Year:  2008        PMID: 18248272     DOI: 10.1586/14779072.6.2.175

Source DB:  PubMed          Journal:  Expert Rev Cardiovasc Ther        ISSN: 1477-9072


  6 in total

1.  Preliminary report on the cost effectiveness of ventricular assist devices.

Authors:  Tomoyuki Takura; Shunei Kyo; Minoru Ono; Ryuji Tominaga; Shigeru Miyagawa; Yoshihisa Tanoue; Yoshiki Sawa
Journal:  J Artif Organs       Date:  2015-08-05       Impact factor: 1.731

Review 2.  Cost-effectiveness analysis of TAVR.

Authors:  Michael J Reardon
Journal:  Methodist Debakey Cardiovasc J       Date:  2012 Apr-Jun

3.  Quality of life and functional status in patients surviving 12 months after left ventricular assist device implantation.

Authors:  Jeremiah G Allen; Eric S Weiss; Justin M Schaffer; Nishant D Patel; Susan L Ullrich; Stuart D Russell; Ashish S Shah; John V Conte
Journal:  J Heart Lung Transplant       Date:  2009-10-17       Impact factor: 10.247

4.  Cost-effectiveness of heart failure therapies.

Authors:  Luis E Rohde; Eduardo G Bertoldi; Livia Goldraich; Carísi A Polanczyk
Journal:  Nat Rev Cardiol       Date:  2013-04-23       Impact factor: 32.419

Review 5.  Emerging ventricular assist devices for long-term cardiac support.

Authors:  Rajan Krishnamani; David DeNofrio; Marvin A Konstam
Journal:  Nat Rev Cardiol       Date:  2010-01-12       Impact factor: 32.419

6.  Ethical challenges with the left ventricular assist device as a destination therapy.

Authors:  Aaron G Rizzieri; Joseph L Verheijde; Mohamed Y Rady; Joan L McGregor
Journal:  Philos Ethics Humanit Med       Date:  2008-08-11       Impact factor: 2.464

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.